The data displays the availability of new cancer drugs that were launched in 2012-2016, as of December 2017, by country. At this time, 47 out of 55 new cancer drugs were available in the U.S. Thus, the U.S. had the highest availability rate among all countries.
Global | 55 | ||
United States | 46 | 1 | 8 |
Germany | 42 | 2 | 11 |
United Kingdom | 38 | 3 | 14 |
Italy | 28 | 8 | 19 |
France | 29 | 6 | 20 |
Canada | 31 | 2 | 22 |
Spain | 20 | 11 | 24 |
South Korea | 21 | 8 | 26 |
Japan | 22 | 6 | 27 |
Australia | 23 | 5 | 27 |
Mexico | 22 | 5 | 28 |
Poland | 18 | 7 | 30 |
Brazil | 12 | 12 | 31 |
Russia | 16 | 8 | 31 |
Turkey | 6 | 13 | 36 |
India | 5 | 5 | 45 |
China | 4 | 5 | 46 |